Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation.

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia & Lymphoma Pub Date : 2025-05-29 DOI:10.1080/10428194.2025.2512025

Roberta S Azevedo, Luis Fayad, Rashmi Kanagal-Shamanna, Sanam Loghavi, Shimin Hu, Carlos E Bueso-Ramos, Koji Sasaki, Tareq Abuasab, Fareed Khawaja, Hannah Goulart, Iman Abou Dalle, Gautam Borthakur, Naveen Pemmaraju

引用次数: 0

查看原文本刊更多论文

KRAS突变患者ras相关白质增生性疾病（RALD）和Rosai-Dorfman病的治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia & Lymphoma 医学-血液学

CiteScore

4.10

自引率

3.80%

发文量

384

审稿时长

1.8 months

期刊介绍： Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor